Work

Trends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study

Year: 2026

Type: article

Abstract: Primary effusion lymphoma (PEL) is a rare and aggressive B-cell non-Hodgkin lymphoma (NHL) that predominantly affects patients with human immunodeficiency virus infection and is strongly associated with human herpes virus 8 (HHV-8) infection. Due to its rarity, the current understanding of PEL's epidemiology and management is largely derived from case reports and small retrospective studies. Using the SEER-17 database, we conducted a retrospective analysis of adults with pathologically confirmed primary effusion lymphoma diagnosed between 2001-2021. Patients were stratified into two time periods (2001-2010 and 2011-2021) to assess temporal trends. Age-adjusted incidence rates, relative survival (RS), overall survival (OS), and lymphoma-specific survival (LSS) were calculated using flexible parametric survival models. Competing risk analysis was performed to evaluate cumulative incidence of lymphoma-specific death. Among 236 patients (median age 51 years, 88% male), 82 were diagnosed in 2001-2010 and 154 in 2011-2021. Age-adjusted incidence rates increased from 1.0 to 1.6 cases per 10,000,000 person-years between periods (p = 0.004). Five-year RS improved from 21% to 37%, with median OS increasing from 4 to 12 months. On multivariable analysis, the more recent period showed significant improvements in OS (HR = 0.65; 95% CI, 0.44-0.97) and LSS (HR = 0.56; 95% CI, 0.36-0.86), with reduced cumulative incidence of lymphoma-specific death (HR = 0.49; 95% CI, 0.33-0.74). In our population-level analysis of PEL, we report a significant improvement in survival outcomes between 2001-2021, likely reflecting advances in both lymphoma treatment and HIV management. However, despite these improvements, OS remains low underscoring the need for prioritizing these patients to clinical trials with novel therapies.

Source: Hematological Oncology

DOI: 10.1002/hon.70168

Authors: John L. Vaughn, Gardenia Taza, Malak Munir, Sravani Rimmalapudi, Narendranath Epperla

Institutions: NYU Grossman Long Island School of Medicine, New York University, Cedars-Sinai Medical Center, Huntsman Cancer Institute

Language: English

Topic: Viral-associated cancers and disorders

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,650